Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
10:1719-1726 (2015) Shibai A, Takahashi Y, Ishizawa Y, Motooka D, Nakamura S, Ying B-W, Tsuru S
doi: 10.3390/nu9121286 150 DaiHWangLLiLHuangZYeL
Visvabharathy L, Hanson B, Orban Z, Lim PH, Palacio NM, Jain R, et al
During the following 26 weeks of treatment (extension phase), discontinuations as a result of adverse events occurred in 2.4% of patients in the T-T group (patients treated with tesamorelin for Week 0-26 and with tesamorelin for Week 26-52) and 5.2% of patients in the T-P group (patients treated with tesamorelin for Week 0-26 and with placebo for Week 26-52)
US$ 24.93
US$ 29.93
